- Home
- HRTX vs TCRX Comparison
HRTX vs TCRX Comparison
Compare HRTX & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRTX | TCRX |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.2M | 49.4M |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HRTX | TCRX |
|---|---|---|
| Price | $0.29 | $0.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.50 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 2.0M | 1.2M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $154,904,000.00 | $10,325,000.00 |
| Revenue This Year | $15.28 | N/A |
| Revenue Next Year | $20.29 | $19.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.36 | ★ 266.65 |
| 52 Week Low | $0.26 | $0.29 |
| 52 Week High | $1.58 | $2.57 |
Technical Indicators
Market Signals| Indicator | HRTX | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 29.52 |
| Support Level | N/A | $0.29 |
| Resistance Level | N/A | $1.27 |
| Average True Range (ATR) | 0.00 | 0.03 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 47.39 |
Price Performance
Historical ComparisonAbout HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.